BIOMAT Database Logo BIOMAT Database Logo

Enantiomeric 2',3'-dideoxycytidine derivatives are potent human immunodeficiency virus inhibitors in cell cultures. 1994

G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
Laboratoire de Chimie Bioorganique, URA CNRS 488, Université de Montpellier-II, Sciences et Techniques du Languedoc, Montpellier, France.

2',3'-dideoxy-beta-L-cytidine (beta-L-DDC) and its 5-fluoro derivative (beta-L-5-F-DDC) have been stereospecifically synthesized by a multi-step reaction sequence from L-xylose and their anti-HIV properties examined. Among these two L-enantiomers, the hitherto unknown beta-L-5-F-DDC emerged as a potent anti-HIV-1 and HIV-2 compound in different cell culture systems, with selectivity indices similar or superior to those of the currently licensed drug DDC which has the natural beta-D configuration.

UI MeSH Term Description Entries
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669
D016047 Zalcitabine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. 2',3'-Dideoxycytidine,Dideoxycytidine,ddC (Antiviral),HIVID Roche,Hivid,NSC-606170,2',3' Dideoxycytidine,NSC 606170,NSC606170

Related Publications

G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
Pharmacodynamics of 2',3'-dideoxycytidine: an inhibitor of human immunodeficiency virus.
May 1990, The American journal of medicine,
G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
Aryl phosphate derivatives of 3'-deoxythymidine are not potent anti-human immunodeficiency virus agents.
September 1998, Antiviral chemistry & chemotherapy,
G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.
January 1987, Biochemical and biophysical research communications,
G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro.
January 1987, The Journal of biological chemistry,
G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus.
November 2013, Journal of medicinal chemistry,
G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
Dideoxycytidine (ddC): a potent antiretroviral agent for human immunodeficiency virus infection. An introduction.
May 1990, The American journal of medicine,
G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.
December 1994, Antimicrobial agents and chemotherapy,
G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection.
December 1989, Journal of the American Academy of Dermatology,
G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
In vitro toxicity and metabolism of 2',3'-dideoxycytidine, an inhibitor of human immunodeficiency virus infectivity.
January 1991, Chemico-biological interactions,
G Gosselin, and C Mathé, and M C Bergogne, and A M Aubertin, and A Kirn, and R F Schinazi, and J P Sommadossi, and J L Imbach
Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
December 2009, Journal of medicinal chemistry,
Copied contents to your clipboard!